Hørsholm, Denmark and Cambridge, MA, US, October 9th, 2018 – Oncology Venture A/S (“Oncology Venture”) today announced that members of its senior management team are scheduled to make a number of investor presentations during the fourth quarter of 2018. CEO Peter Buhl will present on two occasions: at Sedermeradagen in Gothenburg and at the BIO-Europe conference in Copenhagen. CCO Claus Frisenberg Pedersen will present at a networking event held by Thamhaksa Company AB in Malmö. COO Ulla Hald Buhl will present at a member conference arranged by My Money Invest & Moneypenny in Copenhagen. Most events are free of charge. Please, see below for more details.
|Date and time||Organiser||Place||Registration|
| October 11th
15.50 – 16.15
|Sedermera Fondkommission|| Elite Park Avenue Hotel,
411 36 Göteborg
|Please register here to attend: https://www.sedermera.se/sv/evenemang/2018-10-11/sedermeradagen-goteborg-2018|
| November 7th
9.45 – 10.30
| Thamhaksa Company AB
Moneypenny & My Money Invest
| MAQS Advokatbyrå,
211 18 Malmö
Center Blvd. 5,
Kronprinsesse Sofies Vej 35,
| To attend, RSVP to Veeradeth Thamhaksa, firstname.lastname@example.org by October 26th to confirm your attendance.
Please register here to attend:
Please register here to attend:
For further information, please contact:
| For investor inquiries
Ulla Hald Buhl, IR & Communication
Telephone +45 21 70 10 49
| For media inquiries
Thomas Pedersen, Frontpage PR & Communications
Telephone +45 60 62 93 90
About Oncology Venture A/S
Oncology Venture A/S, a merger between Oncology Venture A/S (formerly MPI A/S) and Oncology Venture Sweden AB, is engaged in the research and development of anti-cancer drugs via its wholly-owned subsidiary, Oncology Venture Product Development ApS. Oncology Venture uses Drug Response Prediction – DRP® -to significantly increase the probability of success in clinical trials. DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 29 out of 37 clinical studies that were examined and is currently demonstrating promising results in an ongoing phase 2 study prospectively using LiPlaCis® and its DRP® to track, match and treat patients with metastatic breast cancer. The DRP® alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are first screened, and only the patients most likely to respond to the treatment will be treated. Via a more well-defined patient group, risks and costs are reduced while the development process becomes more efficient.
The current OV product portfolio includes: LiPlaCis®, a liposomal formulation of cisplatin in an ongoing Phase 2 trial for breast cancer; 2X-121 a PARP inhibitor in an ongoing Phase 2 for breast cancer; dovitinib, which will enter Phase 2 trials for indications dependent on further Dovitinib-DRP retrospective/prospective analysis of studies completed by Novartis. 2X-111, a liposomal formulation of doxorubicin under manufacturing for Phase 2 in breast cancer; irofulven, for which a Phase 2 is planned for prostate cancer; and APO010, an immuno-oncology product in Phase 1/2 for multiple myeloma.
Oncology Venture has spun out two companies as Special Purpose Vehicles: Oncology Venture U.S. Inc. (previously 2X Oncology Inc.), a US-based precision medicine company focusing on developing 2X-121 and 2X-111, and OV-SPV 2, a Danish company that will test and develop dovitinib. Oncology Venture A/S has an ownership of 98% in Oncology Venture US and 55% of dovitinib with an opportunity to acquire further 30%.
Learn more at oncologyventure.com.
DRP® is a registered trademark of Oncology Venture A/S.
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OV’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OV’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OV undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.